YOLONDA RAWLS: Open Payments
NPI 1053986174 · DALLAS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465 in 20 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $159 · 2025 $465
Food & beverage: $426Education: $39
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
| SANOFI-AVENTIS U.S. LLC | 3 | $65 |
| GlaxoSmithKline, LLC. | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Exact Sciences Corporation | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| Lundbeck LLC | 1 | $39 |
| Lilly USA, LLC | 2 | $36 |
| Novo Nordisk Inc | 1 | $24 |
| Amgen Inc. | 1 | $20 |
Products named: REXULTI, TZIELD, TRELEGY ELLIPTA, Auvelity, Cologuard Collection Kit, AIRSUPRA, MOUNJARO, OTEZLA.
Industry payments across GA — which companies pay providers there.
